SCHEMBL5875715

SCHEMBL5875715

NC(=O)c1nc(CC(=O)NCC2CC2)cs1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
TDP1 Q9NUW8 1/20 0.40
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
PDE4B Q07343 1/20 0.39
FPR3 P25089 1/20 0.38
FPR2 P25090 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
HRH1 P35367 1/20 0.36
SHMT1 P34896 2/20 0.36
SHMT2 P34897 2/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5240161 0.94 NPC1 (0.46) KDM4ETP53SMN1; SMN2NPC1RAB9A
SCHEMBL5875718 0.83 GABRA5 (0.54) KDM4ETDP1SMN1; SMN2MEN1KMT2A
SCHEMBL5875662 0.80 SMN1; SMN2 (0.45) KDM4ETP53SMN1; SMN2MEN1KMT2A
SCHEMBL5244525 0.78 HPGD (0.43) KDM4ETP53SMN1; SMN2MEN1KMT2A
SCHEMBL5240163 0.77 GABRA5 (0.50) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5875862 0.75 ALDH1A1 (0.58) KDM4EMEN1KMT2ARAB9AALDH1A1
SCHEMBL2745279 0.74 GABRA5 (0.46) KDM4ETDP1TP53SMN1; SMN2MEN1
SCHEMBL5875710 0.73 MEN1 (0.41) KDM4ETDP1TP53SMN1; SMN2MEN1
SCHEMBL11130654 0.73 HSD17B10 (0.62) KDM4ETP53SMN1; SMN2MEN1KMT2A
SCHEMBL17709961 0.73 HTR6 (0.35) KDM4ETP53SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006504796-A 2006-02-09 JP claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US claimed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP disclosed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US disclosed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders APP, PARK7, IAPP KDM4E 4396/4885TDP1 327/4885TP53 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.